Hematopoietic growth factors in colorectal cancer patients

被引:37
作者
Mroczko, B
Szmitkowski, M
Okulczyk, B
机构
[1] Med Acad Bialystok, Dept Biochem Diagnost, PL-15276 Bialystok, Poland
[2] Med Acad Bialystok, Detp Gen Surg 2, Bialystok, Poland
关键词
hematopoietic growth factors; colorectal cancer;
D O I
10.1515/CCLM.2003.098
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Hematopoietic growth factors (HGFs) are involved in the regulation of growth and spread of cancer. Therefore, in the present study, we have investigated in colorectal cancer patients the serum levels of selected HGFs, such as stem cell factor (SCF), interleukin 3 (IL-3), granulocyte-macrophage-colony stimulating factor (GM-CSF), and M-CSF in relation to controls and to the classical tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in colorectal cancer. Additionally, we have compared the serum levels of cytokines with tumor site and stage and other clinical characteristics such as age and sex. We also defined the receiver-operating characteristics (ROC) curve for HGFs and classical tumor markers. The tested cytokines were measured in 70 patients with colorectal cancer and in 40 healthy subjects. HGFs were determined using enzyme-linked immunosorbent assay (ELISA). CEA and CA 19-9 were measured by microparticle enzyme immunoassay. There were significant differences in the levels of circulating SCF, IL-3, M-CSF, GM-CSF, and CEA and CA 19-9 in the colorectal cancer patients compared to the control group. The levels of M-CSF and CEA were significantly higher in patients with a more advanced tumor stage. The significant positive correlation was observed between the CEA and CA 19-9 concentrations. The M-CSF serum levels correlated positively with the tested tumor markers. The M-CSF area under the ROC curve was the largest. These results suggest that M-CSF is, among the tested HGFs, the best candidate for a colorectal cancer tumor marker.
引用
收藏
页码:646 / 651
页数:6
相关论文
共 23 条
[1]  
[Anonymous], AJCC CANC STAGING MA
[2]  
AVALOS BR, 1990, BLOOD, V75, P851
[3]  
BERDEL WE, 1992, SEMIN ONCOL, V19, P41
[4]  
CHAMBERS SK, 1995, CANCER RES, V55, P1578
[5]   Cytokines and advanced cancer [J].
Dunlop, RJ ;
Campbell, CW .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2000, 20 (03) :214-232
[6]  
JASS JR, 1989, HISTOLOGICAL TYPING, P29
[7]  
KAIRISTO V, 1993, CLIN CHEM, V39, P2298
[8]  
LAHM H, 1994, CANCER RES, V54, P3700
[9]  
LAHM H, 1995, CELL GROWTH DIFFER, V6, P1111
[10]  
McDermott RS, 2002, EUR CYTOKINE NETW, V13, P121